Skip to main content

Press releases | May 23, 2025

Fried Frank acted as counsel to Centerview Partners as financial advisor to Vigil Neuroscience, Inc. (NASDAQ: VIGL) (“Vigil”) in its $600 million sale to Sanofi (NASDAQ: SNY) (“Sanofi”). Vigil is a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases. Sanofi is a French multinational pharmaceutical and healthcare company. 

The team was led by partner Roy Tannenbaum.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.